Correction in Conclusions Section

Overview

This report addresses a correction in the conclusions of a clinical trial comparing extended-release and sublingual buprenorphine in pregnant adults with opioid use disorder (OUD). The corrected conclusion highlights that extended-release buprenorphine resulted in higher rates of illicit opioid abstinence during pregnancy compared to sublingual buprenorphine.

Background

Opioid use disorder (OUD) during pregnancy poses significant risks to both maternal and infant health. Effective treatment options, such as buprenorphine, are critical for managing OUD in pregnant individuals. Recent clinical trials have provided insights into the efficacy of different formulations of buprenorphine, emphasizing the importance of accurate reporting in clinical findings.

Data Highlights

No numerical data is presented in the correction notice.

Key Findings

• The corrected conclusion states that extended-release buprenorphine led to higher rates of illicit opioid abstinence during pregnancy than sublingual buprenorphine.
• The trial involved 140 pregnant adults with OUD.
• Mean proportion of weekly urine samples negative for illicit opioids was 82.5% for XR vs 72.6% for SL buprenorphine.
• Postpartum abstinence rates were similar in both groups by 12 months, around 60%.
• Serious maternal adverse events were less frequent with XR buprenorphine during pregnancy and postpartum.
• Infant outcomes regarding treatment for neonatal opioid withdrawal syndrome were not significantly different between groups.

Clinical Implications

Clinicians should consider the benefits of extended-release buprenorphine for pregnant patients with OUD, particularly in terms of achieving higher rates of abstinence. Accurate reporting of clinical trial results is essential for guiding treatment decisions and improving patient outcomes.

Conclusion

The correction in the conclusions section underscores the importance of precise communication in clinical research. Extended-release buprenorphine may offer significant advantages in managing OUD during pregnancy.

References

1. JAMA Internal Medicine, 2026 -- Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum: A Randomized Clinical Trial
2. Acta Neuropathologica — Erratum: Structural Adaptations in the Motor Cortex and White Matter Associated with Parkinson's Disease
3. Journal of Neuro-Oncology — Amendment to: Pediatric Central Nervous System Tumors in Patients Aged Under 5: Insights on Treatment Challenges, Survival Rates, and Long-Term Outcomes
4. American Journal of Epidemiology — Erratum Regarding Basic Sensitivity Analysis for Differential Measurement Errors
5. Acta Neuropathologica — Erratum: The Role of Intraneuronal β‑CTF Fragment Aggregation in Inducing Aβ‑Independent Lysosomal-Autophagic Pathology
6. CDC - Treatment of Opioid Use Disorder Before, During, and After Pregnancy
7. Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum: A Randomized Clinical Trial | Trials | JAMA Internal Medicine | JAMA Network
8. Buprenorphine-naloxone versus buprenorphine for opioid use disorder during pregnancy: A systematic review and meta-analysis - ScienceDirect